Defunct Company
Total Trials
14
As Lead Sponsor
13
As Collaborator
1
Total Enrollment
861
NCT00091377
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase 1/2
Role: Lead Sponsor
Start: Aug 31, 2004
Completion: Mar 31, 2008
NCT00382811
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Phase: Phase 3
Start: Oct 31, 2006
Completion: Apr 30, 2011
NCT00557037
A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer
Phase: Phase 2
Start: Nov 30, 2007
Completion: Nov 30, 2009
NCT01401868
Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors
Phase: Phase 1
Start: Sep 30, 2011
Completion: Jan 31, 2013
NCT01544322
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Start: May 31, 2012
Completion: Aug 31, 2014
NCT02100007
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
Start: Apr 30, 2014
Completion: Apr 30, 2016
NCT02521389
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143
Start: Jun 29, 2015
Completion: Feb 24, 2017
NCT02914938
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Start: Oct 31, 2016
Completion: Mar 29, 2023
NCT03547115
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
Start: May 31, 2018
Completion: Mar 31, 2025
NCT03768505
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Start: Jun 25, 2019
Completion: Mar 24, 2023
NCT04745832
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Start: Aug 13, 2021
Completion: Mar 20, 2023
NCT05209308
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
Start: Nov 22, 2022
Completion: Mar 15, 2023
NCT05604417
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Role: Collaborator
Start: Jan 31, 2023
Completion: Dec 1, 2026
NCT05824559
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
Start: Aug 7, 2023
Completion: Jul 23, 2024